Tuesday, February 22, 2022


  • On Feb. 11, as part of the FDA’s effort to protect consumers, the agency issued a warning letter to CytoDyn Inc. for making representations in a promotional context that leronlimab, a drug that has not been approved or authorized by the FDA, is safe and effective for use in treating COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.

No comments: